{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T10:49:50Z","timestamp":1766659790651,"version":"3.48.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR210079"],"award-info":[{"award-number":["RR210079"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Overexpression of human epidermal growth factor receptor 2 (HER2) has been implicated as a molecular driver of numerous solid tumor subtypes. An antibody drug conjugate (ADC) directed to HER2, trastuzumab-deruxtecan, recently gained tumor-agnostic FDA approval for the treatment of advanced HER2-positive (IHC 3+) solid tumors. Here, we present a patient with HER2-positive invasive poorly differentiated scrotal carcinoma treated with trastuzumab-deruxtecan. The treatment resulted in a complete response, with a tolerable side effect profile and ongoing treatment-free survival. Our case adds to the literature suggesting clinical benefit of the use of trastuzumab-deruxtecan in HER2-positive tumors, and underscores the importance of molecular testing for patients with rare tumor subtypes.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf398","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:33:27Z","timestamp":1764592407000},"source":"Crossref","is-referenced-by-count":0,"title":["Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-7817","authenticated-orcid":false,"given":"Mia","family":"Hofstad","sequence":"first","affiliation":[{"name":"Simmons Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Simmons Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Southwestern Medical Center , Dallas, TX 75390,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-3531","authenticated-orcid":false,"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Simmons Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2025122505463512200_oyaf398-B1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3390\/genes13112065","article-title":"Antibody-drug conjugates for the treatment of HER2-positive breast cancer","volume":"13","author":"Najjar","year":"2022","journal-title":"Genes (Basel)"},{"key":"2025122505463512200_oyaf398-B2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025122505463512200_oyaf398-B3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"author":"FDA","key":"2025122505463512200_oyaf398-B4"},{"key":"2025122505463512200_oyaf398-B5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"2025122505463512200_oyaf398-B6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025122505463512200_oyaf398-B7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025122505463512200_oyaf398-B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025122505463512200_oyaf398-B9","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","author":"Sheng","year":"2025","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf398\/65675405\/oyaf398.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf398\/65675405\/oyaf398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf398\/65675405\/oyaf398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T10:46:43Z","timestamp":1766659603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf398\/8363225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf398","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12,1]]},"article-number":"oyaf398"}}